Evidence map›Paper›PMID 28252832›Full record

ArticleMolecular oncology2017

Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52.

Jugal Bharat Joshi, Divya Patel, Derrick J Morton, Pankaj Sharma, Jin Zou, Dhanushka Hewa Bostanthirige, Yamini Gorantla, Peri Nagappan, Shravan Kumar Komaragiri, Jeffrey C Sivils and 5 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. The chaperone system in cancer therapies: Hsp90.Journal of molecular histology · 2023
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. FKBP Ligands-Where We Are and Where to Go?Frontiers in pharmacology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Jugal Bharat JoshiCenter for Cancer Research and Therapeutic Development, Clark Atlanta University, GA, USA.
Divya PatelCenter for Cancer Research and Therapeutic Development, Clark Atlanta University, GA, USA.
Derrick J MortonCenter for Cancer Research and Therapeutic Development, Clark Atlanta University, GA, USA.
Pankaj SharmaCenter for Cancer Research and Therapeutic Development, Clark Atlanta University, GA, USA.
Jin ZouCenter for Cancer Research and Therapeutic Development, Clark Atlanta University, GA, USA.
Dhanushka Hewa BostanthirigeCenter for Cancer Research and Therapeutic Development, Clark Atlanta University, GA, USA.
Yamini GorantlaCollege of Pharmacy, Mercer University, Atlanta, GA, USA.
Peri NagappanCenter for Cancer Research and Therapeutic Development, Clark Atlanta University, GA, USA.
Shravan Kumar KomaragiriCenter for Cancer Research and Therapeutic Development, Clark Atlanta University, GA, USA.
Jeffrey C SivilsDepartment of Biological Sciences, Border Biomedical Research Center, University of Texas at El Paso, TX, USA.
Huan XieCollege of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA.
Ravi PalaniappanCollege of Pharmacy, Mercer University, Atlanta, GA, USA.
Guangdi WangDepartment of Chemistry, RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA, USA.
Marc B CoxDepartment of Biological Sciences, Border Biomedical Research Center, University of Texas at El Paso, TX, USA.
Jaideep ChaudharyCenter for Cancer Research and Therapeutic Development, Clark Atlanta University, GA, USA.
Clark Atlanta University · USCenter for Cancer Research · USMercer University Health Sciences Center · USThe University of Texas at El Paso · USTexas Southern University · USXavier University of Louisiana · US

Funding

Xavier's RCMI Cancer Research ProgramG12MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI D'AMOUR, GENE, WANG, GUANGDI · 2012 to 2018
$15.7M
THEORY OF PLANNED BEHAVIOR VS ETHNICITY /PHYSICAL ACTIVIG12RR003062 · NCRR · CLARK ATLANTA UNIVERSITY · PI BROWN, CARLTON B · 1985 to 2011
$15.5M
TRAINNING COREP20MD002285 · NIMHD · CLARK ATLANTA UNIVERSITY · PI CHAUDHARY, JAIDEEP · 2007 to 2016
$10.9M
Technologies/Resources for Core LaboratoriesG12MD007590 · NIMHD · CLARK ATLANTA UNIVERSITY · PI KHAN, SHAFIQ A · 2012 to 2018
$7.6M
Inhibitor of Differentiation Gene Expression and Function in Prostate CellsR01CA128914 · NCI · CLARK ATLANTA UNIVERSITY · PI CHAUDHARY, JAIDEEP · 2009 to 2013
$1.4M
NCI NIH HHS R01 CA128914NCRR NIH HHS G12 RR003062NIMHD NIH HHS G12 MD007590NIMHD NIH HHS G12 MD007595NIMHD NIH HHS P20 MD002285
6 · The paper itself

Abstract

Castration-resistant prostate cancer (CRPC) is the emergence of prostate cancer cells that have adapted to the androgen-depleted environment of the prostate. In recent years, targeting multiple chaperones and co-chaperones (e.g., Hsp27, FKBP52) that promote androgen receptor (AR) signaling and/or novel AR regulatory mechanisms have emerged as promising alternative treatments for CRPC. We have shown that inactivation of inhibitor of differentiation 4 (ID4), a dominant-negative helix loop helix protein, promotes de novo steroidogenesis and CRPC with a gene expression signature that resembles constitutive AR activity in castrated mice. In this study, we investigated the underlying mechanism through which loss of ID4 potentiates AR signaling. Proteomic analysis between prostate cancer cell line LNCaP (L+ns) and LNCaP lacking ID4 (L(-)ID4) revealed elevated levels of Hsp27 and FKBP52, suggesting a role for these AR-associated co-chaperones in promoting constitutively active AR signaling in L(-)ID4 cells. Interestingly, protein interaction studies demonstrated a direct interaction between ID4 and the 52-kDa FK506-binding protein (FKBP52) in vitro, but not with AR. An increase in FKBP52-dependent AR transcriptional activity was observed in L(-)ID4 cells. Moreover, pharmacological inhibition of FKBP52-AR signaling, by treatment with MJC13, attenuated the tumor growth, weight, and volume in L(-)ID4 xenografts. Together, our results demonstrate that ID4 selectively regulates AR activity through direct interaction with FKBP52, and its loss, promotes CRPC through FKBP52-mediated AR signaling.

Indexed as

AnilidesAnimalsCell Line, TumorCell NucleusCyclohexanesGene Expression Regulation, NeoplasticGene Knockdown TechniquesHSP27 Heat-Shock ProteinsHumansImmunohistochemistryInhibitor of Differentiation ProteinsMaleMice, SCIDNeoplasm ProteinsPhenotypeProstatic Neoplasms, Castration-ResistantAnilidesCyclohexanesHSP27 Heat-Shock ProteinsID4 protein, humanInhibitor of Differentiation ProteinsN-(2,3-dichlorophenyl)cyclohexanecarboxamideNeoplasm ProteinsReceptors, Androgentacrolimus binding protein 4Tacrolimus Binding Proteinsandrogen receptorcastration-resistantFKBP51FKBP52HLHHsp27Hsp90ID4MJC13prostate cancerPSA

Identifiers

PMID28252832
PMCPMC5378613
OpenAlexW2591739428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.